ABSTRACT OF THE DISCLOSURE

The present invention describes compounds comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compounds of the present invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of X_1-X_2- X_3-X_4-X_5-X_6-X_7-X_8, wherein: X_1 is Phe, or is absent; X_2 is His or Ala; X_3 is Glu, Ser, Ala, Asn, Lys, or Cys; X_4 is Asn, Phe, Gln, Pro, Ser, or Ala; X_5 is Trp; X_6 is Pro, Arg, Glu, Gly, Cys, or Lys; X_7 is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and X_8 is Phe, Gly, or is absent.